Home    Back

 Drug    DrugBank | All Description Patterns

   e.g. "Sirolimus", "Adalimumab"

A    B    C    D    E    F    G    H     I     J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    other

85 / 12,170 descriptions found* Show info (disease name, etc.) on mouse-over.
 No.   Drug (Description in trials)   DrugBank   KEGG DRUG *   KEGG GENES * 
 [Number of genes] 		  KEGG PATHWAY 
 [Number of pathways] 		  Disease ID * 
 [Number of diseases] 
 1   0.5 mg budesonide effervescent tablet for orodispersible use   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 2   1 mg budesonide effervescent tablet for orodispersible use   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 3   1mg budesonide effervescent tablet for orodispersible use   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 4   2mg budesonide effervescent tablet for orodispersible use   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 5   5 mg montelukast   Montelukast   D00529, D08229   [1] CYSLTR1   [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction   [1]
98 
 6   Ak002   -   -   -   -   [1]
98 
 7   Allergy immunotherapy (allergy shots)   -   -   -   -   [1]
98 
 8   Apt-1011   -   -   -   -   [1]
98 
 9   Barium   Barium   -   -   -   [1]
98 
 10   Beclomethasone dipropionate   Beclomethasone dipropionate   D00689, D07495   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [2]
97,
98 
 11   Bethanechol   Bethanechol   D01000   [5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   [11] Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway   [1]
98 
 12   Budesonide   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [9]
66,
93,
94,
95,
96,
97,
98,
228,
299 
 13   Budesonide 0.5mg orodispersible tablet twice daily   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 14   Budesonide 1mg orodispersible tablet twice daily   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 15   Budesonide [0.4mg/ml] viscous suspension   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 16   Budesonide oral suspension   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 17   Budesonide oral suspension [0.2 mg/ml]   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 18   Budesonide plus prevacid   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 19   Buet 0.5 mg   -   -   -   -   [1]
98 
 20   Buet 1mg   -   -   -   -   [1]
98 
 21   Buet 2mg   -   -   -   -   [1]
98 
 22   Buu 0.4mg/ml   -   -   -   -   [1]
98 
 23   Cromolyn   Cromoglicic acid   D00526, D07753   -   -   [2]
85,
98 
 24   Dexlansoprazole   Dexlansoprazole   D08903   [2] ATP4A, ATP4B   [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   [1]
98 
 25   Dupilumab   Dupilumab   D10354   [1] IL4R   [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation   [1]
98 
 26   Dupilumab (blinded)   Dupilumab   D10354   [1] IL4R   [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation   [1]
98 
 27   Dupilumab (open-label)   Dupilumab   D10354   [1] IL4R   [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation   [1]
98 
 28   Esomeprazole   Esomeprazole   D01984, D04056, D07917, D09339   [2] ATP4A, ATP4B   [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   [6]
6,
46,
86,
98,
298,
299 
 29   Eur-1100   -   -   -   -   [1]
98 
 30   Florence 30 µg/ml   -   -   -   -   [1]
98 
 31   Florence 60 µg/ml   -   -   -   -   [1]
98 
 32   Florence 90 µg/ml   -   -   -   -   [1]
98 
 33   Flovent   Fluticasone propionate   D01708   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 34   Flovent (fluticasone propionate)   Fluticasone propionate   D01708   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 35   Fluticasone   Fluticasone   D07981   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [4]
98,
228,
299,
306 
 36   Fluticasone mdi   Fluticasone   D07981   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 37   Fluticasone propionate   Fluticasone propionate   D01708   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [3]
98,
228,
306 
 38   Honey   Honey   D06776   -   -   [2]
57,
98 
 39   Infliximab   Infliximab   D02598   [1] TNF   [61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [22]
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
95,
96,
97,
98,
162,
164,
269,
271 
 40   Inhaled/swallowed budesonide   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 41   Intubated with propofol (ip)   Propofol   D00549   [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   [7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   [1]
98 
 42   Intubated with sevoflurane (is)   Sevoflurane   D00547   -   -   [1]
98 
 43   Lansoprazole   Lansoprazole   D00355   [2] ATP4A, ATP4B   [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   [6]
63,
71,
98,
166,
222,
299 
 44   Losartan   Losartan   D00357, D08146   [1] AGTR1   [14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   [18]
13,
17,
19,
46,
58,
66,
67,
85,
96,
97,
98,
113,
164,
167,
179,
215,
222,
299 
 45   Losartan potassium   Potassium   D08403   -   -   [4]
98,
167,
179,
215 
 46   Mepolizumab   Mepolizumab   D04923   [1] IL5   [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   [4]
44,
45,
98,
162 
 47   Mepolizumab 100 mg   Mepolizumab   D04923   [1] IL5   [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   [1]
98 
 48   Mepolizumab 300 mg   Mepolizumab   D04923   [1] IL5   [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   [1]
98 
 49   Monitor   Methamidophos   -   -   -   [12]
2,
11,
13,
19,
46,
49,
58,
70,
85,
98,
298,
300 
 50   Montelukast   Montelukast   D00529, D08229   [1] CYSLTR1   [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction   [5]
13,
46,
85,
98,
228 
 51   Montelukast/ singulair   Montelukast   D00529, D08229   [1] CYSLTR1   [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction   [1]
98 
 52   Nasonex   Mometasone furoate   D00690   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 53   Nitric oxide   Nitric oxide   D00074   -   -   [7]
46,
85,
86,
98,
251,
294,
299 
 54   Oc000459   -   -   -   -   [1]
98 
 55   Omalizumab   Omalizumab   D05251   [1] FCER1A   [4] Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway   [6]
53,
65,
98,
162,
226,
299 
 56   Omeprazole   Omeprazole   D00455, D01207, D05259, D05261   [2] ATP4A, ATP4B   [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   [15]
6,
8,
13,
46,
51,
85,
96,
97,
98,
225,
271,
282,
294,
298,
299 
 57   Omeprazole 20mg bid   Omeprazole   D00455, D01207, D05259, D05261   [2] ATP4A, ATP4B   [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   [1]
98 
 58   Oral budesonide   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 59   Oral budesonide suspension (mb-9)   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 60   Oral budesonide suspension (obs)   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 61   Oral cromolyn sodium   Cromoglicic acid   D00526, D07753   -   -   [1]
98 
 62   Oral viscous budesonide   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 63   Oral viscous budesonide (ovb)   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 64   Potassium   Potassium   D08403   -   -   [9]
46,
66,
67,
98,
115,
167,
179,
215,
235 
 65   Propofol   Propofol   D00549   [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   [7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   [8]
6,
21,
22,
34,
46,
84,
98,
296 
 66   Qax576   -   -   -   -   [4]
51,
85,
96,
98 
 67   Reslizumab   Reslizumab   D08985   [1] IL5   [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   [3]
44,
45,
98 
 68   Rpc4046   -   -   -   -   [1]
98 
 69   Sb-240563   -   -   -   -   [3]
44,
45,
98 
 70   Sch55700   -   -   -   -   [1]
98 
 71   Sevoflurane   Sevoflurane   D00547   -   -   [5]
6,
21,
22,
98,
296 
 72   Sirolimus   Sirolimus   D00753   [1] MTOR   [43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   [30]
13,
17,
34,
35,
36,
46,
51,
60,
62,
63,
65,
66,
67,
85,
89,
96,
98,
137,
157,
158,
192,
222,
277,
278,
279,
280,
281,
283,
285,
331 
 73   Steroid and proton pump inhibitor therapy   -   -   -   -   [1]
98 
 74   Sucralfate   Sucralfate   D00446   -   -   [1]
98 
 75   Swallowed fluticasone   Fluticasone   D07981   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 76   Technetium tc 99m   Technetium tc-99m   -   -   -   [1]
98 
 77   Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms   Lansoprazole   D00355   [2] ATP4A, ATP4B   [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   [1]
98 
 78   Viaskin milk 500 mcg   -   -   -   -   [1]
98 
 79   Viscous/swallowed budesonide   Budesonide   D00246   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [1]
98 
 80   Vitamin d   Vitamin d   -   -   -   [18]
13,
19,
41,
46,
49,
50,
68,
93,
95,
96,
98,
179,
222,
228,
235,
274,
298,
299 
 81   Vonoprazan   Vonoprazan   -   -   -   [2]
63,
98 
 82   Wheat   Wheat   D06902   -   -   [2]
98,
266 
 83   Xanthan gum   Xanthan gum   D06333   -   -   [1]
98 
 84   Xylose   Xylose   D06346   -   -   [1]
98 
 85   Zofran - no intubation   -   -   -   -   [1]
98 

Back to top